{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T14:28:24Z","timestamp":1793456904416,"version":"4.5.0"},"reference-count":75,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Of all achievements in medicine, the successful treatment of tuberculosis has had one of the greatest impacts on society. Tuberculosis was a leading cause of disease and a mortal enemy of humanity for millennia. The first step in finding a cure was the discovery of the cause of tuberculosis by Robert Koch in 1882. The sanatorium movement that began shortly afterward in Europe, and soon spread to the United States, brought attention to the plight of afflicted persons, and catalyzed public health action. The antituberculosis benefit of streptomycin was announced in 1945, although application was limited by the rapid development of resistance. para-Aminosalicylic acid, also discovered in 1945, when combined with streptomycin was found to greatly reduce the occurrence of drug resistance. In 1952, isoniazid opened the modern era of treatment; it was inexpensive, well tolerated, and safe. In the early 1960s, ethambutol was shown to be effective and better tolerated than para-aminosalicylic acid, which it replaced. In the 1970s, rifampin found its place as a keystone in the therapy of tuberculosis. The use of rifampin enabled the course of treatment to be reduced to nine months. Incorporation of pyrazinamide into the first-line regimen led to a further reduction of treatment duration to six months. Treatment of multiple drug\u2013resistant tuberculosis remains a difficult problem requiring lengthy treatment with toxic drugs. However, shortened regimens show promise, and two new drugs, bedaquiline and delamanid, have demonstrated effectiveness in preliminary studies and are being used for extensively drug-resistant tuberculosis.<\/jats:p>","DOI":"10.1513\/annalsats.201509-632ps","type":"journal-article","created":{"date-parts":[[2015,12,11]],"date-time":"2015-12-11T12:12:46Z","timestamp":1449835966000},"page":"1749-1759","source":"Crossref","is-referenced-by-count":194,"title":["Treatment of Tuberculosis. A Historical Perspective"],"prefix":"10.1093","volume":"12","author":[{"given":"John F.","family":"Murray","sequence":"first","affiliation":[{"name":"Curry International Tuberculosis Center, Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean E.","family":"Schraufnagel","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Illinois at Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip C.","family":"Hopewell","sequence":"additional","affiliation":[{"name":"Curry International Tuberculosis Center, Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,12,1]]},"reference":[{"key":"2026012303362594000_bib1","article-title":"Robert Koch: a life in medicine and bacteriology","author":"Brock","year":"1999"},{"key":"2026012303362594000_bib2","volume-title":"\u00c9tudes sur la tuberculose.","author":"Villemin","year":"1868"},{"key":"2026012303362594000_bib3","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1164\/rccm.200312-1639OE","article-title":"Mycobacterium tuberculosis and the cause of consumption: from discovery to fact","volume":"169","author":"Murray","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303362594000_bib4","first-page":"221","article-title":"Die Aetiologie der Tuberculose","volume":"19","author":"Koch","year":"1882","journal-title":"Berl Klin Wochenschr"},{"key":"2026012303362594000_bib5","first-page":"161","article-title":"Hermann Brehmer and the origins of tuberculosis sanatoria","volume":"15","author":"Daniel","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026012303362594000_bib6","article-title":"Robert Koch. Leipzig: Akademische Verlagsgesellschaft","author":"Heymann","year":"1932"},{"key":"2026012303362594000_bib7","volume-title":"An autobiography","author":"Trudeau","year":"1916"},{"key":"2026012303362594000_bib8","article-title":"Captain of death: the story of tuberculosis","author":"Daniel","year":"1997"},{"key":"2026012303362594000_bib9","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1164\/rccm.201501-0135OE","article-title":"Tuberculosis and World War I","volume":"192","author":"Murray","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303362594000_bib10","first-page":"73","article-title":"The surgery for pulmonary tuberculosis","volume":"125","author":"Gaensler","year":"1982","journal-title":"Am Rev Respir Dis"},{"key":"2026012303362594000_bib11","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1164\/rccm.200307-1016OE","article-title":"Bill Dock and the location of pulmonary tuberculosis: how bed rest might have helped consumption","volume":"168","author":"Murray","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303362594000_bib12","first-page":"51","article-title":"A concurrent comparison of home and sanatorium treatment of pulmonary tuberculosis in South India","volume":"21","author":"Tuberculosis Chemotherapy Centre","year":"1959","journal-title":"Bull World Health Organ"},{"key":"2026012303362594000_bib13","author":"Nobelprize.org. Gerhard Domagk\u2014facts.","year":"2014"},{"key":"2026012303362594000_bib14","first-page":"52","article-title":"Chemotherapy of clinical tuberculosis with Promin","volume":"50","author":"Hinshaw","year":"1944","journal-title":"Am Rev Tuberc"},{"key":"2026012303362594000_bib15","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.2307\/4584691","article-title":"The Promin treatment of leprosy: a progress report","volume":"58","author":"Faget","year":"1943","journal-title":"Public Health Rep"},{"key":"2026012303362594000_bib16","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3181\/00379727-55-14461","article-title":"Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria","volume":"55","author":"Schatz","year":"1944","journal-title":"Proc Soc Exp Biol Med"},{"key":"2026012303362594000_bib17","first-page":"773","article-title":"Pay dirt: the story of streptomycin. I. From Waksman to Waksman","volume":"117","author":"Comroe","year":"1978","journal-title":"Am Rev Respir Dis"},{"key":"2026012303362594000_bib18","first-page":"269","article-title":"Streptomycin in experimental tuberculosis","volume":"52","author":"Feldman","year":"1945","journal-title":"Am Rev Tuberc"},{"key":"2026012303362594000_bib19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0140-6736(46)91184-1","article-title":"Determination of pathogenicity of tubercle bacilli by their intermediate metabolism","volume":"1","author":"Lehmann","year":"1946","journal-title":"Lancet"},{"key":"2026012303362594000_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0140-6736(46)91185-3","article-title":"para-Aminosalicylic acid in the treatment of tuberculosis","volume":"1","author":"Lehmann","year":"1946","journal-title":"Lancet"},{"key":"2026012303362594000_bib21","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1164\/rccm.200402-140OE","article-title":"A century of tuberculosis","volume":"169","author":"Murray","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303362594000_bib22","first-page":"957","article-title":"Pay dirt: the story of streptomycin. II. Feldman and Hinshaw; Lehmann","volume":"117","author":"Comroe","year":"1978","journal-title":"Am Rev Respir Dis"},{"key":"2026012303362594000_bib23","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jama.1946.02870480024007","article-title":"Treatment of tuberculosis with streptomycin; a summary of observations on one hundred cases","volume":"132","author":"Hinshaw","year":"1946","journal-title":"J Am Med Assoc"},{"key":"2026012303362594000_bib24","first-page":"597","article-title":"para-Aminosalicylic acid treatment in pulmonary tuberculosis","volume":"61","author":"Swedish National Association against Tuberculosis, Therapeutic Trials Committee","year":"1950","journal-title":"Am Rev Tuberc"},{"key":"2026012303362594000_bib25","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1136\/bmj.2.4688.1073","article-title":"Treatment of pulmonary tuberculosis with streptomycin and para-aminosalicylic acid; a Medical Research Council investigation","volume":"2","author":"Medical Research Council","year":"1950","journal-title":"BMJ"},{"key":"2026012303362594000_bib26","first-page":"27","article-title":"Chemotherapy of human tuberculosis with hydrazine derivatives of isonicotinic acid; preliminary report of representative cases","volume":"13","author":"Robitzek","year":"1952","journal-title":"Q Bull Sea View Hosp"},{"key":"2026012303362594000_bib27","first-page":"402","article-title":"Hydrazine derivatives of isonicotinic acid (Rimifon, Marsilid) in the treatment of active progressive caseous-pneumonic tuberculosis; a preliminary report","volume":"65","author":"Robitzek","year":"1952","journal-title":"Am Rev Tuberc"},{"key":"2026012303362594000_bib28","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1136\/bmj.1.4911.435","article-title":"Various combinations of isoniazid with streptomycin or with P.A.S. in the treatment of pulmonary tuberculosis; seventh report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee","volume":"1","author":"Medical Research Council","year":"1955","journal-title":"BMJ"},{"key":"2026012303362594000_bib29","doi-asserted-by":"crossref","first-page":"87s","DOI":"10.1183\/09031936.02.00309102","article-title":"Tuberculosis therapy: past, present and future","volume":"36","author":"Iseman","year":"2002","journal-title":"Eur Respir J Suppl"},{"key":"2026012303362594000_bib30","first-page":"891","article-title":"A new synthetic compound with antituberculous activity in mice: ethambutol (dextro-2,2\u2032-(ethylenediimino)-di-1-butanol)","volume":"83","author":"Thomas","year":"1961","journal-title":"Am Rev Respir Dis"},{"key":"2026012303362594000_bib31","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1749-6632.1966.tb45533.x","article-title":"Ethambutol: a substitute for para-aminosalicylic acid in regimens for pulmonary tuberculosis","volume":"135","author":"Ferebee","year":"1966","journal-title":"Ann N Y Acad Sci"},{"key":"2026012303362594000_bib32","first-page":"177","article-title":"Ethambutol in the initial treatment of pulmonary tuberculosis. U.S. Public Health Service tuberculosis therapy trials","volume":"107","author":"Doster","year":"1973","journal-title":"Am Rev Respir Dis"},{"key":"2026012303362594000_bib33","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1159\/000220462","article-title":"Rifampicin: a new orally active rifamycin","volume":"11","author":"Maggi","year":"1966","journal-title":"Chemotherapy"},{"key":"2026012303362594000_bib34","doi-asserted-by":"crossref","first-page":"S402","DOI":"10.1093\/clinids\/5.Supplement_3.S402","article-title":"History of the development of rifampin","volume":"5","author":"Sensi","year":"1983","journal-title":"Rev Infect Dis"},{"key":"2026012303362594000_bib35","first-page":"1102","article-title":"British Thoracic and Tuberculosis Association. Short-course chemotherapy in pulmonary tuberculosis: a controlled trial by the British Thoracic and Tuberculosis Association","volume":"2","year":"1976","journal-title":"Lancet"},{"key":"2026012303362594000_bib36","first-page":"1249","article-title":"The effect of nicotinic acid amide on experimental tuberculosis of white mice","volume":"33","author":"McKenzie","year":"1948","journal-title":"J Lab Clin Med"},{"key":"2026012303362594000_bib37","first-page":"851","article-title":"Pyrazinamide-isoniazid in tuberculosis. III. Observations with reduced dosage of pyrazinamide","volume":"72","author":"Muschenheim","year":"1955","journal-title":"Am Rev Tuberc"},{"key":"2026012303362594000_bib38","first-page":"579","article-title":"Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis","volume":"119","author":"Singapore Tuberculosis Service\/British Medical Research Council","year":"1979","journal-title":"Am Rev Respir Dis"},{"key":"2026012303362594000_bib39","first-page":"236","article-title":"The in vitro action of cycloserine on M. tuberculosis","volume":"72","author":"Barclay","year":"1955","journal-title":"Am Rev Tuberc"},{"key":"2026012303362594000_bib40","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1136\/bmj.2.5207.1207","article-title":"Ethionamide","volume":"2","author":"Riddell","year":"1960","journal-title":"BMJ"},{"key":"2026012303362594000_bib41","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1749-6632.1958.tb54688.x","article-title":"Kanamycin: its discovery","volume":"76","author":"Umezawa","year":"1958","journal-title":"Ann N Y Acad Sci"},{"key":"2026012303362594000_bib42","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1749-6632.1966.tb45540.x","article-title":"Capreomycin in original treatment cases of pulmonary tuberculosis","volume":"135","author":"Popplewell","year":"1966","journal-title":"Ann N Y Acad Sci"},{"key":"2026012303362594000_bib43","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1164\/artpd.1959.79.5.690","article-title":"How can elimination of tuberculosis as a public health problem be achieved","volume":"79","author":"Holm","year":"1959","journal-title":"Am Rev Tuberc"},{"key":"2026012303362594000_bib44","first-page":"305","article-title":"Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review","volume":"15","author":"Steingart","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026012303362594000_bib45","doi-asserted-by":"crossref","first-page":"394","DOI":"10.7196\/SAMJ.6344","article-title":"The pharmacokinetics of enteral antituberculosis drugs in patients requiring intensive care","volume":"103","author":"Koegelenberg","year":"2013","journal-title":"S Afr Med J"},{"key":"2026012303362594000_bib46","doi-asserted-by":"crossref","first-page":"5819","DOI":"10.1128\/AAC.05561-11","article-title":"Plasma drug activity assay for treatment optimization in tuberculosis patients","volume":"55","author":"Heysell","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012303362594000_bib47","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.5588\/ijtld.12.0277","article-title":"New drugs for the treatment of tuberculosis: hope and reality","volume":"16","author":"Grosset","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026012303362594000_bib48","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"2026012303362594000_bib49","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1164\/rccm.200512-1953OC","article-title":"Weekly rifapentine\/isoniazid or daily rifampin\/pyrazinamide for latent tuberculosis in household contacts","volume":"173","author":"Schechter","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303362594000_bib50","first-page":"1650","article-title":"Recommendations for use of an isoniazid\u2013rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection","volume":"60","author":"Centers for Disease Control and Prevention (CDC)","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026012303362594000_bib51","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(98)11467-8","article-title":"Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid","volume":"353","author":"Vernon","year":"1999","journal-title":"Lancet"},{"key":"2026012303362594000_bib52","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1164\/rccm.2302005","article-title":"Role of isoniazid in once-weekly rifapentine treatment of pulmonary tuberculosis","volume":"167","author":"Mitchison","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303362594000_bib53","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1093\/infdis\/jis461","article-title":"Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium","volume":"206","author":"Dorman","year":"2012","journal-title":"J Infect Dis"},{"key":"2026012303362594000_bib54","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(09)60333-0","article-title":"Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial","volume":"373","author":"Conde","year":"2009","journal-title":"Lancet"},{"key":"2026012303362594000_bib55","doi-asserted-by":"crossref","first-page":"e67030","DOI":"10.1371\/journal.pone.0067030","article-title":"Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients","volume":"8","author":"Jawahar","year":"2013","journal-title":"PLoS One"},{"key":"2026012303362594000_bib56","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1164\/rccm.201303-0604OC","article-title":"Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis","volume":"188","author":"Koh","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303362594000_bib57","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1164\/rccm.200310-1380OC","article-title":"Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis","volume":"169","author":"Nuermberger","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303362594000_bib58","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1183\/09031936.00022912","article-title":"Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis","volume":"40","author":"Sotgiu","year":"2012","journal-title":"Eur Respir J"},{"key":"2026012303362594000_bib59","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.5588\/ijtld.12.0144","article-title":"Systematic review of clofazimine for the treatment of drug-resistant tuberculosis","volume":"17","author":"Gopal","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026012303362594000_bib60","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1128\/AAC.05293-11","article-title":"Sterilizing activity of novel TMC207- and PA-824\u2013containing regimens in a murine model of tuberculosis","volume":"55","author":"Tasneen","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012303362594000_bib61","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.5588\/ijtld.11.0752","article-title":"In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters","volume":"16","author":"Xu","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026012303362594000_bib62","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1128\/AAC.01204-07","article-title":"Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis","volume":"52","author":"Rustomjee","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012303362594000_bib63","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1313865","article-title":"Multidrug-resistant tuberculosis and culture conversion with bedaquiline","volume":"371","author":"Diacon","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012303362594000_bib64","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1371\/journal.pmed.0030466","article-title":"OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice","volume":"3","author":"Matsumoto","year":"2006","journal-title":"PLoS Med"},{"key":"2026012303362594000_bib65","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa1112433","article-title":"Delamanid for multidrug-resistant pulmonary tuberculosis","volume":"366","author":"Gler","year":"2012","journal-title":"N Engl J Med"},{"key":"2026012303362594000_bib66","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1128\/AAC.00849-10","article-title":"PA-824 exhibits time-dependent activity in a murine model of tuberculosis","volume":"55","author":"Ahmad","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012303362594000_bib67","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1128\/AAC.01354-09","article-title":"Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients","volume":"54","author":"Diacon","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012303362594000_bib68","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1128\/AAC.00384-12","article-title":"Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis","volume":"56","author":"Williams","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012303362594000_bib69","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1007\/BF02111491","article-title":"Dormancy of Mycobacterium tuberculosis and latency of disease","volume":"13","author":"Wayne","year":"1994","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026012303362594000_bib70","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jconrel.2014.05.038","article-title":"Respirable nanocarriers as a promising strategy for antitubercular drug delivery","volume":"187","author":"Mehanna","year":"2014","journal-title":"J Control Release"},{"key":"2026012303362594000_bib71","doi-asserted-by":"crossref","first-page":"S325","DOI":"10.1093\/infdis\/jis197","article-title":"Adjunct immunotherapies for tuberculosis","volume":"205","author":"Uhlin","year":"2012","journal-title":"J Infect Dis"},{"key":"2026012303362594000_bib72","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ijid.2014.11.026","article-title":"Tuberculosis vaccines\u2014state of the art, and novel approaches to vaccine development","volume":"32","author":"da Costa","year":"2015","journal-title":"Int J Infect Dis"},{"key":"2026012303362594000_bib73","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1164\/rccm.201304-0650OC","article-title":"Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor","volume":"188","author":"Gupta","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303362594000_bib74","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1166\/jbn.2014.1928","article-title":"siRNA-based therapies for pulmonary diseases","volume":"10","author":"Koli","year":"2014","journal-title":"J Biomed Nanotechnol"},{"key":"2026012303362594000_bib75","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1164\/rccm.200411-1603OE","article-title":"The diagnosis and therapy of tuberculosis during the past 100 years","volume":"171","author":"Mitchison","year":"2005","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/12\/12\/1749\/66552770\/annalsats_12_12_1749.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/12\/12\/1749\/66552770\/annalsats_12_12_1749.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:36:42Z","timestamp":1769157402000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/12\/12\/1749\/8429078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,1]]},"references-count":75,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2015,12,1]]},"published-print":{"date-parts":[[2015,12,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.201509-632ps","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,12]]},"published":{"date-parts":[[2015,12,1]]}}}